- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03249064
Response to Tregs in Innate Immunity Receptor LRP1 (CD91) and Tregs in Periferic Blood Mononuclear Cells in Patients With Non-segmentary Vitiligo
This study aims to evaluate some differences in the immune system between patients with vitiligo and patients without the disease.
These differences will be evaluated by the extraction of peripheral blood that will be analyzed before the treatment and after the treatment that, in the habitual way and at the discretion of the responsible dermatologist.
Patients agreeing to participate in the study will be subjected to extraction of two tubes (20 ml) of peripheral blood (baseline) and after 12 weeks (+/- 5 days) of treatment.
Therefore, neither treatment nor follow-up visits will be modified by participation, but will be the same whether or not participate in the study.
In the case of controls, two peripheral blood tubes (20ml) will be removed in a single participation.
Patients with vitiligo will also be asked to complete questionnaires to measure stress, depression and perception of disease (PSS-10, Skindex-29, HADS, Likert) before and after 12 weeks (+/- 5 days) of therapeutic intervention .
This study will include 20 patients with active non-segmental vitiligo and 10 controls without the disease. The duration of participation in this study will be 12 weeks (+/- 5 days) for patients with vitiligo and a single participation (extraction of 20 ml of peripheral venous blood) for the controls.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Barcelona, Spain, 08025
- Hospital de la Santa Creu i Sant Pau
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patient with vitiligo without treatment
Exclusion Criteria:
- Patient with inmunosupressive disease
- Patient receiving vitiligo treatment
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Vitiligo untreated patients
|
|
Control. Patients without vitiligo
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Tregs levels
Time Frame: Baseline
|
Baseline
|
Tregs levels
Time Frame: 16 weeks
|
16 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
LRP1 (CD91) levels
Time Frame: Baseline
|
Baseline
|
LRP1 (CD91) levels
Time Frame: 16 weeks
|
16 weeks
|
Collaborators and Investigators
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IIBSP-VIT-2015-69
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on VITILIGO
-
PfizerRecruitingStable Nonsegmental Vitiligo | Active Nonsegmental VitiligoUnited States, Spain, Australia, Mexico, Canada, China, Japan, Italy, Turkey, Korea, Republic of, Germany, South Africa, Poland, United Kingdom, Bulgaria
-
PfizerRecruitingStable Nonsegmental Vitiligo | Active Nonsegmental VitiligoJapan, Canada, China, United States
-
Incyte CorporationRecruitingNonSegmental VitiligoGermany, United States, Italy, Poland, Canada, France, Bulgaria, Hungary, United Kingdom
-
Incyte CorporationCompletedNonSegmental VitiligoUnited States, Canada
-
Cairo UniversitySuspended
-
Assiut UniversityUnknown
-
University of TorontoCanadian Interdisciplinary Network Complementary & Alternative Medicine ResearchCompleted
-
University Hospital, GhentNovartisCompletedVitiligo VulgarisBelgium
-
Merck Sharp & Dohme LLCRecruitingNon-segmental VitiligoUnited States, Canada, Australia, Korea, Republic of, Switzerland, Germany, Spain, Chile, France, Israel, Netherlands, Japan, Belgium
Clinical Trials on CD 91 levels
-
Ospedale Generale Di Zona Moriggia-PelasciniOspedale di Vipiteno-Sterzing (SABES-ASDAA)CompletedSupranuclear Palsy, Progressive | Multiple System Atrophy | Primary Parkinsonism | Secondary Vascular Parkinson DiseaseItaly
-
Michael Rapoff, Ph.D.National Institute of Neurological Disorders and Stroke (NINDS)Completed
-
Medical College of WisconsinChildren's Hospital of PhiladelphiaCompletedMalignant Diseases (ie, Leukemia, MDS, Lymphoma) | Non-malignant Diseases (ie, Bone Marrow Failure Syndromes)United States
-
New York State Psychiatric InstituteBayer; National Institute on Aging (NIA)CompletedLate Onset Alzheimer DiseaseUnited States
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedCardiovascular DiseaseUnited States
-
Mashhad University of Medical SciencesTerminatedInteractive CD-based Education
-
Nile TherapeuticsCompletedAcute Decompensated Heart FailureUnited States, Germany, Israel
-
Brooke Army Medical CenterUnknown
-
Shanghai Changzheng HospitalNot yet recruitingAdvanced Hepatocellular Carcinoma
-
Heidelberg UniversityJohannes Gutenberg University Mainz; Heidelberg University, Psychotherapy Research... and other collaboratorsCompletedConduct DisorderGermany